Advaxis, Inc. (ADXS): Price and Financial Metrics


Advaxis, Inc. (ADXS): $0.41

0.00 (-0.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADXS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 492

in industry

ADXS POWR Grades


  • Growth is the dimension where ADXS ranks best; there it ranks ahead of 95.13% of US stocks.
  • The strongest trend for ADXS is in Momentum, which has been heading down over the past 186 days.
  • ADXS ranks lowest in Stability; there it ranks in the 1st percentile.

ADXS Stock Summary

  • ADXS has a higher market value than only 9.26% of US stocks; more precisely, its current market capitalization is $49,578,647.
  • With a price/sales ratio of 26.58, Advaxis Inc has a higher such ratio than 92.48% of stocks in our set.
  • Advaxis Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -28.87%, greater than the shareholder yield of just 9.1% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Advaxis Inc are OIIM, BMRA, KMDA, SEAC, and ALT.
  • ADXS's SEC filings can be seen here. And to visit Advaxis Inc's official web site, go to www.advaxis.com.

ADXS Price Target

For more insight on analysts targets of ADXS, see our ADXS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.25 Average Broker Recommendation 1.5 (Moderate Buy)

ADXS Stock Price Chart Interactive Chart >

Price chart for ADXS

ADXS Price/Volume Stats

Current price $0.41 52-week high $1.57
Prev. close $0.42 52-week low $0.26
Day low $0.39 Volume 4,093,567
Day high $0.42 Avg. volume 11,022,259
50-day MA $0.65 Dividend yield N/A
200-day MA $0.56 Market Cap 57.10M

Advaxis, Inc. (ADXS) Company Bio


Advaxis Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology. The company was founded in 2002 and is based in Princeton, New Jersey.


ADXS Latest News Stream


Event/Time News Detail
Loading, please wait...

ADXS Latest Social Stream


Loading social stream, please wait...

View Full ADXS Social Stream

Latest ADXS News From Around the Web

Below are the latest news stories about Advaxis Inc that investors may wish to consider to help them evaluate ADXS as an investment opportunity.

Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually, on June 4-8, 2021. Presentation Details: Title: A phase 1 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy.Session Type: Poster SessionAbstract Number: 2616Date and Time: June 4, 2021, 9:00 AM (EDT) About Advaxis, Inc.Advaxis, Inc. is a clinical-stage biotechnology compan...

Yahoo | April 28, 2021

ADVAXIS MAKING BOLD STEPS IN NEW CANCER STUDIES AND AGREEMENT WITH COLUMBIA UNIVERSITY

Advaxis, Inc. (NASDAQ: ADXS), CEO Ken Berlin presented at the Benzinga Biotech Small-Cap Conference on March 24, 2021. Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, is making new waves as it takes definitive steps to prove that the company is “no longer your grandfather’s Advaxis,” according to company CEO Ken Berlin. Among Advaxis’s new steps is an agreement with the Columbia University Irving Medical Center to fund a Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer. The company has also announced new data relating to developing a novel flow immunophenotyping assay to accurately evaluate total PD-1 expression as a pharmacodynamic marker during PD-1 bloc...

Yahoo | April 20, 2021

Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PRINCETON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into definitive agreements with two healthcare-focused, institutional investors for the purchase of (i) 17,577,400 shares of common stock , (ii) 7,671,937 pre-funded warrants (the “Pre-Funded Warrants”) to purchase 7,671,937 shares of common stock and (iii) registered common share purchase warrants to purchase 11,244,135 shares of common stock. The Company has also agreed to issue to the investors, in a concurrent private placement, unregistered common share purchase warrants to purchase 14,005,202 shares of the Company’s common stock. Each share ...

Yahoo | April 12, 2021

Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting

Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade Assay enables determination of PD-1 expression independent of PD-1 receptor status, accounting for both free and drug-bound PD-1 Results confirm on-mechanism activation of innate and adaptive immune responses in patients with demonstrated clinical benefit from ADXS-503 treatment in combination with pembrolizumab PRINCETON, N.J., April 10, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Precision for Medicine, a specialized services company supporting next generation approaches to drug development and commer...

Yahoo | April 10, 2021

Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference

Exciting and insightful biotech news was front and center at the Benzinga Biotech Small Cap Conference, a two-day event that kicked off virtually Wednesday. Viviane Mason, a biopharma industry veteran and investor, set the ball rolling with a session on what an investor should look for when investing in biotech stocks. Mason explained the long-winding drug approval process and the catalysts an investor needs to watch. Mason suggested looking for companies that have recently raised capital, as she said it's a signal a company has a cash runway. The following are biotech companies that investors heard from at the Benzinga conference. Presentations Lantern Pharma Inc. (NASDAQ: LTRN): Lantern CEO Panna Sharma recommends leveraging data — especially on similar classes of drugs in the market ...

Yahoo | March 25, 2021

Read More 'ADXS' Stories Here

ADXS Price Returns

1-mo -38.45%
3-mo -64.04%
6-mo 3.98%
1-year -46.97%
3-year -98.46%
5-year -99.63%
YTD 17.58%
2020 -59.34%
2019 -69.91%
2018 -93.31%
2017 -60.34%
2016 -28.83%

Continue Researching ADXS

Here are a few links from around the web to help you further your research on Advaxis Inc's stock as an investment opportunity:

Advaxis Inc (ADXS) Stock Price | Nasdaq
Advaxis Inc (ADXS) Stock Quote, History and News - Yahoo Finance
Advaxis Inc (ADXS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.6854 seconds.